The “T2 Protect AD” study is being held in more than 30 states in the U.S. to test troriluzole, a drug that might help slow or even stop the progression of Alzheimer’s, according to CBS News.
The Alzheimer’s Disease Cooperative Study (ADCS), a national university based research organization at the University of California, San Diego, linked Alzheimer’s to “glutamate problems in the brain”. The faulty regulation of glutamate leads “to brain cell dysfunction and disease”. “Troriluzole is a drug that modulates glutamate, protecting against neuron loss,” ACDS claimed.
In 1995, troriluzole was approved by the FDA to slow the progression of Amyotrophic Lateral Sclerosis (ALS).
The study will take place over a 48 week period and is meant to help people who already have mild to moderate Alzheimer’s.